Pharma and healthcare: sector news on Tuesday 27 October 2026
Average tone +2.2 (slightly positive) across 5 companies with relevant coverage, from 72 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +9.2 | 35 | Most coverage covered very favourable late-stage cancer results presented at ESMO 2026, chiefly for the stomach cancer drug and for Imfinzi and Tagrisso, along with plans to seek approval and supportive broker comments. |
| GSK | +9.3 | 29 | Coverage was dominated by encouraging cancer trial data presented at ESMO, covering bone, ovarian and rectal cancer. |
| Smith & Nephew | −5.3 | 4 | Coverage centred on the collapse of talks with Johnson & Johnson to combine their orthopaedics businesses, which leans negative. |
| Convatec | −6.5 | 2 | Coverage centred on a UK court ruling allowing a former employee to combine patent benefits in a £366M compensation claim involving Convatec. |
| Haleon | +4.2 | 2 | Coverage was light, with a positive piece on Haleon's hands-on health education campaign and a more neutral market commentary on how the shares might fare in a more selective FTSE 100 environment. |
Strongest stories in the sector
- +10.0 Gastric drug markedly improves survival in later-line patients.
- +10.0 Late-stage study shows survival doubled with stomach cancer drug.
- +10.0 Three cancer medicines produced favourable late-stage results.
- +10.0 Experimental gastric drug doubles survival in study.
- +10.0 Most rectal patients avoided surgery and chemotherapy after treatment.
- +10.0 High tumour clearance rate in rectal cancer trial.
- +10.0 Stomach cancer trial results give patients hope, favourable coverage.
- +10.0 Large mortality reduction in gastric Phase III study.
- +10.0 ADC data comes in ahead of analyst hopes.
- +10.0 Late-stage trial shows survival gain for gastric drug.
- +10.0 Official release confirms high complete response rate.
- +10.0 Imfinzi shows large mortality benefits in lung and bladder studies.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.